Business Context and Reporting Period
This Form 8-K Current Report, dated December 11, 2018, details the completion of a merger between Akebia Therapeutics, Inc. ("Akebia") and Keryx Biopharmaceuticals, Inc. ("Keryx"). The transaction was consummated on December 12, 2018, resulting in Keryx becoming a wholly-owned subsidiary of Akebia. The filing also covers the results of a special stockholder meeting held on December 11, 2018, and subsequent changes to the Board of Directors.
Key Financial Metrics and Transaction Terms
This filing is a current report regarding corporate events and does not contain standard financial statements (revenue, profit, cash flow, or margins) for a reporting period. Key transaction-specific financial terms include:
- Exchange Ratio: Each outstanding share of Keryx common stock was converted into 0.37433 of a share of Akebia Common Stock.
- Fractional Shares: Cash was paid in lieu of fractional shares.
- Director Compensation: New non-employee directors are eligible for an annual cash retainer of $40,000 and options to purchase 25,000 shares of Common Stock.
- Registration Rights: Akebia entered into a Registration Rights Agreement with Baupost Group Securities, L.L.C., granting customary rights to register shares issued to Baupost upon the merger's consummation.
Material Changes Versus Prior Period
The primary material change is the structural consolidation of Keryx into Akebia. Specific changes include:
- Capital Structure: Issuance of new Akebia Common Stock to Keryx shareholders based on the 0.37433 exchange ratio.
- Board Composition: Five directors (Muneer A. Satter, Michael D. Clayman, Duane Nash, Ronald C. Renaud, Jr., and Michael S. Wyzga) resigned. Five new directors (Mark J. Enyedy, Steven C. Gilman, Michael T. Heffernan, Jodie P. Morrison, and Michael Rogers) were elected, previously serving on the Keryx Board.
- Leadership: Adrian Adams was designated as the new Chairperson of the Board.
- Equity Plan: The Akebia 2014 Incentive Plan was amended to allow for the substitution of awards from acquired entities without reducing the share reserve.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance, revenue outlook, or management commentary on future performance. It notes that the Merger Agreement contains representations and warranties that were made solely for the purpose of the agreement and may be subject to qualifications or contractual standards of materiality different from those applicable to stockholders. The filing incorporates the full text of the Merger Agreement and Registration Rights Agreement by reference for complete terms.
Investor Verification Checklist
- Verify the exact number of Akebia shares issued to Keryx shareholders by reviewing the final post-merger capitalization table.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific covenants, indemnification obligations, and conditions.
- Confirm the details of the Registration Rights Agreement with Baupost (Exhibit 10.1) regarding demand registration limitations and indemnification.
- Monitor future filings for the appointment of Board committee members, as these were not determined at the time of this filing.
- Check subsequent filings for the impact of the merger on Akebia's consolidated financial statements and cash position.